Trial Profile
An open-label combination study of capecitabine and standard paclitaxel therapy as first or second line therapy in women with metastatic breast carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Roche
- 08 Sep 2005 New trial record.